• Consulting Address
    Harley Street at University College Hospital, 5th Floor, Macmillan Cancer Centre, Huntley Street, London WC1E 6AG
  • NHS Base
    National Hospital for Neurology & Neurosurgery, Queen Square, London WC1N 3BG; University College London Hospitals NHS Foundation Trust, 235 Euston Road, London NW1 2BU; Mount Vernon Cancer Centre, Rickmansworth Road, Northwood HA6 2RN
  • Qualifications
    MBBS, MSc, PhD, FRCP
  • Research Interests
    Chemotherapy, clinical trials in brain cancer
  • Speciality
  • Sub Speciality
    Brain cancer, chemotherapy, new agents
  • Year Qualified


Dr Paul Mulholland is a medical oncologist who exclusively treats brain cancer. He is a consultant at the National Hospital for Neurology and Neurosurgery (part of UCLH) and Mount Vernon Cancer Centre, and he is Chair of the HCA Cancer Care brain and central nervous system tumour board. Dr Mulholland is also an honorary senior lecturer at University College London and a training programme director. He did his doctoral research in genomic profiling in brain cancer at the Cancer Research UK London Research Institute. This led to his focus on developing biomarkers and targets for therapy in brain cancer, including the clinical trial portfolio of novel agents in brain cancer which he now runs at UCLH and nationally. 

Dr Mulholland is Clinical Lead in a European consortium called Dartrix, a multidisciplinary European collaboration to advance next generation targeted hyperthermic cancer treatment for glioblastoma.  

Committee membership

2012 – London Cancer Brain and Spine Pathway Board Member

2013 – Royal Society of Medicine Oncology Section (2014 President Elect)

2014 – CRUK New Agents Committee

2014 –  French National Cancer Institute Funding Committee (Institut National du Cancer) (INCa)

Studies in set-up

DARTRIX                 A phase I study of targeted hyperthermia in glioblastoma

Recent peer reviewed articles

Thomas Carter, Heather Shaw, Denise Cohn-Brown, Kerry Chester, Paul Mulholland. Ipilimumab and bevacizumab in glioblastoma. J Clin Oncol. 2016 (In press).

Thomas Carter, Paul Mulholland, Kerry Chester. Antibody-Targeted Nanoparticles for Cancer Treatment. Future Medicine, 2016. (In press).

Nicholas F Brown, Daniel Krell and Paul Mulholland. Chemotherapy for Brain Tumours. Book Chapter. Oxford Textbook of Neurosurgery, 2016 (In press).

Tracy Batchelor, Paul Mulholland, Bart Neyns, L. Burt Nabors, Mario Campone, Antje Wick, Warren Mason, Tom Mikkelsen, Surasak Phuphanich, Lynn Ashby, John DeGroot, Rao Gattamaneni, Lawrence Cher, Mark Rosenthal, Franz Payer, Rakesh Jain, A. Gregory Sorensen, John Xu, Qi Liu, Martin van den Bent. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol. 2013 Sep 10;31(26):3212-3218.

Daniel Krell, Paul Mulholland, Adam E. Frampton, Jonathan Krell, Justin Stebbing, Chiara Bardella. Isocitrate Dehydrogenase mutations in tumourigenesis and their potential role as novel therapeutic targets. Future Oncology 2013 Dec;9(12):1923-35.

D Ulahannan, M B Kovac, P J Mulholland, J-B Cazier and I Tomlinson. Technical and implementation issues in using next-generation sequencing of cancers in clinical practice. Br J Cancer. 2013 Aug 20;109(4):827-35.

Tim Forshew, Paul Lewis, Adam Waldman, David Peterson, Mark Glaser, Cathryn Brock, Denise Sheer and Paul J. Mulholland. Three Different Brain Tumours Evolving from a Common Origin. Oncogenesis. 2013 Apr 1;2:e41.